"Insulin, Long-Acting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
| Descriptor ID |
D049528
|
| MeSH Number(s) |
D06.472.699.587.200.300 D12.644.548.586.200.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Insulin, Long-Acting".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Long-Acting".
This graph shows the total number of publications written about "Insulin, Long-Acting" by people in this website by year, and whether "Insulin, Long-Acting" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin, Long-Acting" by people in Profiles.
-
What is the best approach to glycaemic control in patients with type 2 diabetes? Diabetes Obes Metab. 2015 Feb; 17(2):105-6.
-
Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab. 2015 Feb; 17(2):202-6.
-
Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014 Jun; 16(6):483-91.
-
Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014 Mar; 16(3):193-205.
-
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013 Aug; 15(8):760-6.
-
Methods to enhance delivery of prandial insulin and basal-prandial insulin. Diabetes Obes Metab. 2013 Mar; 15 Suppl 1:11-7.
-
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012 Jun 15; 11(12):2314-26.
-
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62.
-
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1498-507.
-
Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007 Nov; 55(11):1735-40.